Bioidentical Hormone Therapy for Women: A Modern Framework

For two decades after the Women's Health Initiative was misread, an entire generation of women was told hormone therapy was too risky to consider. The data has since been re-examined, and the modern consensus is far more nuanced: for most women starting therapy within ten years of menopause, the benefits substantially outweigh the risks.

Bioidentical hormone replacement therapy (BHRT) uses estradiol, progesterone, and often low-dose testosterone that are molecularly identical to what your body produced in your reproductive years. Delivery routes matter — transdermal estradiol carries a different risk profile than oral, and micronized progesterone is preferred over synthetic progestins.

We dose to relief of symptoms and to physiologic lab ranges, not to youthful peaks. Hot flashes, sleep disruption, brain fog, mood, libido, vaginal health, and bone density are all in scope. So is cardiovascular and breast risk assessment, which we revisit annually.

Testosterone in women is the most under-discussed piece of this puzzle. Properly dosed, it can be transformative for energy, libido, and lean mass. Improperly dosed, it causes acne and unwanted hair growth — which is why monitoring matters.

The right question is no longer 'is hormone therapy safe?' It's 'what dose, what route, and what monitoring plan fits your specific risk profile and goals?'